NCT06636617View on ClinicalTrials.gov

177Lu-JH04 in Patients with FAP-Positive Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 21, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Patients with Advanced Metastatic FAP-Positive Tumors
Interventions
DRUG

3.70 GBq (100 mCi) of 177Lu-JH04

All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.

DRUG

5.55 GBq (150 mCi) of 177Lu-JH04

All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04

DRUG

7.40 GBq (200 mCi) of 177Lu-JH04

All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04

Trial Locations (1)

350005

RECRUITING

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER